Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

32.66
-3.5800-9.88%
Post-market: 32.900.2400+0.73%19:54 EDT
Volume:4.83M
Turnover:159.68M
Market Cap:3.94B
PE:-10.79
High:38.00
Open:38.00
Low:31.59
Close:36.24
Loading ...

Avidity Biosciences Inc. Unveils Presentation on Advancements in RNA Therapeutics and AOC Platform for Neuromuscular Diseases

Reuters
·
7 hours ago

Avidity data strengthens accelerated approval case, says H.C. Wainwright

TIPRANKS
·
10 hours ago

Avidity Biosciences Receives Buy Rating Due to Promising FSHD Program Developments and Accelerated FDA Approval Pathway

TIPRANKS
·
13 hours ago

Avidity Biosciences price target raised to $54 from $48 at BofA

TIPRANKS
·
13 hours ago

Avidity Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Yesterday

Avidity Biosciences Inc : Chardan Capital Markets Raises Target Price to $75 From $65

THOMSON REUTERS
·
Yesterday

BRIEF-Avidity Reports Positive Phase 1/2 Data For Del-Brax In FSHD Patients

Reuters
·
Yesterday

Avidity announces accelerated approval regulatory pathway for Del-Brax

TIPRANKS
·
Yesterday

Avidity Biosciences Announces Positive Topline Phase 1/2 Fortitude™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated Fshd Participants

THOMSON REUTERS
·
Yesterday

Avidity Biosciences Inc - Data Support Planned Accelerated Approval Bla Submission in H2 2026

THOMSON REUTERS
·
Yesterday

Avidity Biosciences Secures Accelerated Approval Pathway for Del-Brax in the U.S. and Launches Global Phase 3 Study for FSHD Treatment

Reuters
·
Yesterday

Kathleen P. Gallagher, Chief Program Officer, Reports Disposal of Avidity Biosciences Inc. Common Shares

Reuters
·
05 Jun

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Business Wire
·
30 May

Avidity Biosciences Announces Inducement Grants for New Employees Under 2022 Incentive Plan

Reuters
·
22 May

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
22 May

CRISPR, Sirius Collaborate on RNA Therapy Targeting Blood Clot Disorders

MT Newswires Live
·
20 May

Eli Lilly, Rznomics Collaborate to Develop RNA-Editing Therapies for Hearing Loss Treatment

MT Newswires Live
·
16 May

Circio Secures Additional Funding for RNA Technology and Cancer Vaccine Trials

TIPRANKS
·
13 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
13 May

Eli Lilly Strikes $1B Biotech Deal with Creyon Bio to Accelerate AI-Powered RNA Drug Discovery

TIPRANKS
·
12 May